Swiss pharmaceutical company Roche (RHHBY) is not planning job cuts and its business is healthy, CEO Thomas Schinecker was quoted as saying by a Swiss newspaper on Sunday, according to Reuters. Roche’s share price has fallen far below peaks it scaled in April 2022 and the CEO was questioned about the company’s staffing plans in the context of recent setbacks in its development of drugs to treat cancer, among other illnesses.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- RBC sees justification for Prothena rebound after study miss
- Prothena price target lowered to $22 from $26 at BofA
- Rising High: Exclusive talk with biopharma company HMNC Brain Health
- Prothena partner Roche PADOVA study misses primary endpoint
- Roche announces PADOVA study misses statistical significance